Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Sirukumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Sirukumab?

Sirukumab is an investigational drug.

There have been 11 clinical trials for Sirukumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Polymyalgia Rheumatica. The leading clinical trial sponsors are GlaxoSmithKline, Janssen Research & Development, LLC, and Janssen Pharmaceutical K.K.

There are five US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for Sirukumab
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia RheumaticaGlaxoSmithKlinePhase 3
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled AsthmaGlaxoSmithKlinePhase 2
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell ArteritisGlaxoSmithKlinePhase 3

See all Sirukumab clinical trials

Clinical Trial Summary for Sirukumab

Top disease conditions for Sirukumab
Top clinical trial sponsors for Sirukumab

See all Sirukumab clinical trials

US Patents for Sirukumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sirukumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Sirukumab   Start Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA)   Start Trial
Sirukumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.